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A burgeoning number of studies are demonstrating aluminium in human brain tissue. While 
research has both quantified and imaged aluminium in human brain tissue in neurodegenerative 
and neurodevelopmental disease there are few similar data for brain tissue from non-neurologically 
impaired donors. We have used microwave assisted acid digestion and transversely heated graphite 
furnace atomic absorption spectrometry to measure aluminium in twenty brains from donors without 
recognisable neurodegenerative disease. The aluminium content of 191 tissue samples was invariably 
low with over 80% of tissues having an aluminium content below 1.0 μg/g dry weight of tissue. the data 
for these control tissues were compared with data (measured using identical procedures) for sporadic 
Alzheimer’s disease, familial Alzheimer’s disease, autism spectrum disorder and multiple sclerosis. 
Detailed statistical analyses showed that aluminium was significantly increased in each of these disease 
groups compared to control tissues. We have confirmed previous conclusions that the aluminium 
content of brain tissue in Alzheimer’s disease, autism spectrum disorder and multiple sclerosis is 
significantly elevated. Further research is required to understand the role played by high levels of 
aluminium in the aetiology of human neurodegenerative and neurodevelopmental disease.
Human exposure to aluminium is burgeoning and its entry into and presence within the human body is inev-
itable1–3. There is no ‘aluminium homeostasis’4. The bioinorganic chemistry of aluminium dictates that it will 
‘piggy-back’ upon essential biochemistry and it is such adventitious interactions that determine its fate in the 
human body. The brain is a target tissue for accumulation of aluminium5,6. Long-lived neurones provide intracel-
lular pools, such as citrate, ATP and glutamic acid, where aluminium can remain complexed without necessarily 
disrupting cellular biochemistry7. Aluminium is neurotoxic and is found in brain tissue in extracellular milieu 
associated with neuropathology including senile plaques and neurofibrillary tangles in Alzheimer’s disease8,9. 
While there is no longer any debate as to the presence of aluminium in human brain tissue, there remains the 
question of how much aluminium in brain tissue is too much10. A number of recent studies have provided data 
on aluminium content in brain tissue in Alzheimer’s disease11, multiple sclerosis12 and autism13. The quantitative 
data, supported by aluminium-specific imaging, are invariably reported as being high, higher than expected. 
However, data on the latter, true control data are extremely rare. Brain banks have themselves struggled with 
the concept of what constitutes a true control14. We asked one such brain bank to identify a set of donor brain 
tissues that could act as a control for brains affected and diagnosed with a neurodegenerative disease. The 
majority of control brains available through brain banks are from older donors and so most still show some 
signs of age-related degeneration. Herein we have measured the aluminium content of twenty control brains 
where in each case there was no overt neurodegeneration, no diagnosis of a neurodegenerative disease but some 
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age-related changes in the older donors. We have then compared these data with data, measured under identical 
conditions, for donors having died with diagnoses of Alzheimer’s disease, multiple sclerosis and autism.
Results
control brain tissues. The aluminium content of all tissues ranged from 0.01 (the limit of quantitation) to 
9.28 μg/g dry wt. (Table 1). The majority of tissues (150 out of 191) were below 1.00 μg/g dry wt. though 28, 6 
and 7 tissues were in the range 1.00–1.99, 2.00–2.99 and ≥3.00 μg/g dry wt. respectively. The aluminium content 
of each lobe (mean and SD) were 1.03 (1.64), 1.02 (1.27), 0.95 (0.88), 0.77 (0.92) and 0.51 (0.51) μg/g dry wt. for 
frontal, temporal, parietal, occipital and cerebellum respectively. There were no statistically significant differences 
between aluminium content and age (p-value = 0.7656) or gender (p-value = 0.4005) and even though the cere-
bellum had the lowest content of aluminium, there were no statistically significant differences between any of the 
five brain regions (p-value = 0.2488; Table 2; Fig. 1).
comparison with disease groups. We compared control brain data with each of four treatment groups, 
namely sporadic Alzheimer’s disease (sAD), familial Alzheimer’s disease (fAD), autism spectrum disorder (ASD) 
ID Sex Age F T P O Cb
A002/13 M 90 4.18 0.59 1.06 0.43 0.51
9.28 0.52 0.92 0.77 Lost
A407/13 F 80 0.85 0.80 0.62 0.43 0.05
0.01 0.04 0.80 3.62 0.05
A158/14 F 73 0.84 0.27 0.77 1.76 0.30
0.48 0.32 0.52 0.29 0.82
A132/14 F 66 0.45 0.06 0.62 0.26 1.52
0.43 0.56 2.35 1.05 0.43
A105/14 F 77 0.85 0.47 0.44 0.34 Lost
0.82 0.68 5.09 0.11 0.91
A082/14 M 68 0.70 0.20 0.67 1.17 0.85
0.49 0.46 0.49 4.42 0.10
A177/14 F 67 0.01 1.01 0.29 0.29 0.17
0.46 4.77 0.44 0.40 0.42
A308/14 F 66 0.43 0.49 1.44 0.48 Lost
0.38 0.49 0.40 0.29 Lost
A297/14 M 105 0.77 0.61 1.51 2.52 0.04
0.46 Lost 0.27 0.95 0.20
A007/15 F 74 0.39 0.29 2.19 0.29 0.24
0.69 0.13 1.73 0.30 0.72
A202/15 F 93 1.25 0.16 1.36 0.49 0.69
Lost 0.78 0.91 0.75 0.59
A066/16 M 95 0.38 0.43 0.34 1.01 0.21
1.35 0.57 Lost 0.25 0.55
A006/16 F 68 0.64 0.20 0.74 Lost 0.89
0.21 2.77 0.72 0.83 0.31
A500/16 F 96 0.40 2.00 0.31 0.35 2.68
0.52 0.97 0.21 0.24 0.33
A234/17 F 47 1.47 0.58 1.16 0.52 0.20
0.36 1.30 0.95 1.48 0.76
A103/17 F 55 1.27 1.25 0.73 0.17 0.04
0.30 1.98 1.38 0.23 0.14
A073/14 F 72 4.72 0.81 1.94 0.16 1.03
0.83 1.96 1.30 0.32 0.31
A250/14 F 69 0.40 0.97 0.30 0.45 0.45
0.67 0.92 0.15 1.22 0.61
A242/15 M 82 0.61 0.46 0.61 0.66 Lost
0.35 0.91 0.62 0.43 0.17
A256/17 F 86 0.11 6.65 0.62 0.18 0.55
1.49 1.35 0.09 0.15 0.12
Table 1. Aluminium content (μg/g dry wt. tissue) in brain tissues of control donors. F - frontal; T - temporal; 
P - parietal; O - occipital; Cb - cerebellum - 2 replicate samples for each tissue. Lost - indicates no data due to 
incomplete digestion of tissue.
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and multiple sclerosis (MS). The descriptive statistics for each of these groups are shown in Table 3. The sAD 
group is actually composed of both control donors and donors diagnosed with sporadic Alzheimer’s disease, an 
approximate 50/50 split, see later for a more detailed explanation of this. In addition this group has been analysed 
according to how negative values in the original data set are dealt with, for example; sAD- sporadic Alzheimer’s 
disease (including negative values); sAD+- sporadic Alzheimer’s disease (negative values adjusted to LOQ); 
sAD– - sporadic Alzheimer’s disease (negative values excluded).
Treatment group (sAD; sAD–; sAD + ; fAD; ASD; MS) was the only factor that consistently affected the alu-
minium content of donor brain tissue. This was the case for all statistical analyses carried out including; when 
units were unweighted observations or means of individuals; for both adjustments sAD+ and sAD–; for trun-
cation of outliers; parametric or non-parametric procedures (Table 4). The aluminium content of brain tissue in 
the control group was significantly lower than sAD (P = 0.0006), fAD (P = 0.0020), ASD (P = 0.0123) and MS 
(P < 0.0001) (Fig. 2).
Discussion
We present the first comprehensive data set for the aluminium content of brain tissue in donors without a diagnosis 
of neurodegenerative disease. All donors fulfilled recently revised criteria for control brain tissues14. Approximately 
80% of measured tissues have an aluminium content below 1.0 μg/g dry wt. (Table 1). There are some anomalies, 6 
out of 191 tissues have an aluminium content ≥3.00 μg/g dry wt., and these are worth future investigation to identify 
possible neuropathology. There was no statistically significant relationship between brain aluminium content and 
age of donor and this observation is contrary to a previous investigation of brain aluminium in a neurologically 
normal population15. An explanation may be that herein only two out of twenty donors were below 66 years old. The 
data do support a conclusion that a high content of brain aluminium is not an inevitability of ageing.
Stat/Lobe F T P O Cb
Mean 1.03 1.02 0.95 0.77 0.51
Standard Error 0.26 0.20 0.14 0.15 0.09
Median 0.52 0.59 0.73 0.43 0.42
Mode 0.85 0.20 0.62 0.29 0.05
Standard Deviation 1.64 1.27 0.88 0.92 0.51
Sample Variance 2.71 1.62 0.77 0.84 0.26
Kurtosis 17.44 11.10 12.41 7.81 9.18
Skewness 3.96 3.13 3.01 2.71 2.56
Range 9.27 6.61 5.00 4.31 2.64
Minimum 0.01 0.04 0.09 0.11 0.04
Maximum 9.28 6.65 5.09 4.42 2.68
Sum 40.30 39.78 37.06 30.06 17.96
Count 39 39 39 39 35
Confidence Level 
(95.0%) 0.53 0.41 0.29 0.30 0.17
Table 2. Descriptive statistics for control brain tissues. F - frontal; T - temporal; P - parietal; O - occipital; Cb - 
cerebellum. Aluminium content in μg/g dry weight of tissue.
Figure 1. Aluminium content, μg/g dry wt., of brain tissue for each brain region of the twenty donor controls, 
comprising 5 males and 15 females. Mean and one standard deviation are indicated. For primary data, please see 
Table 1.
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When we compared the new control data set with data produced in an identical manner in donors dying with 
diagnoses of sporadic Alzheimer’s disease (sAD)16, familial Alzheimer’s disease (fAD)11, autism spectrum disor-
der (ASD)13 and multiple sclerosis (MS)12 all of these disease groups had significantly higher brain aluminium 
content. The differences were always highly significant regardless of the method of statistical analysis (Table 4). 
The largest disease group, designated as sAD, was actually composed of approximately equal numbers of donors 
previously described by a brain bank as controls and donors diagnosed with sAD. Unfortunately, information 
discriminating between control and sAD donors was not made available to us17. However, the observation that 
Stat/Group Control* sAD sAD+ sAD- ASD fAD MS
Observations
Mean 0.95 1.69 1.75 1.95 3.17 2.80 3.20
Median 0.60 1.30 1.03 1.17 1.69 1.41 1.20
Std. Deviation 1.21 2.97 2.91 3.01 4.29 4.58 9.30
Maximum 9.28 32.99 32.99 32.99 22.11 35.65 132.64
Minimum 0.01 −4.91 0.01 0.01 0.01 0.01 0.01
Count 156 708 708 636 56 144 330
Means for individuals
Mean 0.94 1.69 1.75 1.96 3.20 2.80 3.24
Median 0.88 1.31 1.44 1.61 3.56 2.44 2.76
Std. Deviation 0.39 1.05 1.37 1.13 1.41 1.60 1.80
Maximum 2.22 4.74 4.92 5.90 4.77 6.55 6.93
Minimum 0.55 0.37 0.47 0.51 1.20 0.34 1.06
Count 20 60 60 60 5 12 14
Table 3. Descriptive statistics for the different groups under comparison. Control - control group; sAD- 
sporadic Alzheimer’s disease (including negative values); sAD+- sporadic Alzheimer’s disease (negative values 
adjusted to LOQ); sAD–sporadic Alzheimer’s disease (negative values excluded); ASD- autism spectrum 
disorder; fAD - familial Alzheimer’s disease; MS - multiple sclerosis. Aluminium content in μg/g dry weight of 
tissue. *Excluding data for cerebellum.
Unweighted Observations
Disease sAD+n = 1394 sAD-n = 1322
ASD v fAD 0.3912 0.3912
ASD v Control <0.0001 <0.0001
ASD v sAD 0.0002 0.0068
ASD v MS 0.0697 0.0697
fAD v Control <0.0001 <0.0001
fAD v sAD 0.0043 0.3970
fAD v MS 0.5880 0.5880
Control v sAD 0.0001 <0.0001
Control v MS <0.0001 <0.0001
sAD v MS 0.1071 1.0000
Individual Means
Disease sAD+n = 111 sAD-n = 111
ASD v fAD 0.9171 0.9171
ASD v Control 0.0123 0.0123
ASD v sAD 0.1649 0.2936
ASD v MS 0.9987 0.9987
fAD v Control 0.0020 0.0020
fAD v sAD 0.0956 0.2198
fAD v MS 0.9940 0.9940
Control v sAD 0.0006 <0.0001
Control v MS <0.0001 <0.0001
sAD v MS 0.0056 0.0347
Table 4. Wilcoxon scores, rank sums (Dwass, Steel, Critchlow-Fligner Method) relating to aluminium data 
(μg/g dry wt.) for unweighted observations and individual means. Control - control group; sAD- sporadic 
Alzheimer’s disease (including negative values); sAD+- sporadic Alzheimer’s disease (negative values adjusted 
to LOQ); sAD–sporadic Alzheimer’s disease (negative values excluded); ASD- autism spectrum disorder; fAD - 
familial Alzheimer’s disease; MS - multiple sclerosis. Significant P values are shown in bold typescript.
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the aluminium content of brain tissue in this group as a whole was significantly higher than the similarly aged 
control group emphasised the likelihood that brain aluminium content is increased in sAD. The data for the 
control group demonstrate that high content of brain aluminium is not an inevitability of living in the aluminium 
age. All disease groups had significantly higher brain aluminium content than the control group in spite of low 
numbers of donor brains, for example only 5 in ASD, and high variability within measured tissues. The disease 
groups, sAD, fAD, ASD and MS shared the characteristics of significant focal deposits of aluminium throughout 
all main lobes of the brain and associated neuropathology and neurodegeneration. Quantitative data, even when 
complemented with high quality aluminium-specific fluorescence microscopy18, do not directly confirm a role 
for aluminium in each of these diseases. However, since there is no debate as to the neurotoxicity of aluminium 
in humans19–21, such data do implicate aluminium in disease aetiology. Animal models of aluminium intoxica-
tion reproduce the neuropathologies and neurodevelopmental effects of human neurodegenerative disease, if not 
the diseases per se22,23. Cell models and in vitro studies demonstrate mechanisms of aluminium toxicity known 
to be involved in human neurodegenerative disease24,25. Perhaps the information that is still missing from our 
understanding of aluminium’s role in each of the diseases compared herein is how much aluminium is too much 
in human brain tissue10. The comparison we have made herein between control brain tissue showing no signs of 
neurodegenerative disease and the disease groups sAD, fAD, ASD and MS is beginning to answer this question. 
Only further measurements on more donor brains will enable a definitive conclusion to be reached on the role 
played by aluminium in human neurodegenerative disease.
Aluminium is not a member of the human metallome4. However, its omnipresence in human tissue and espe-
cially the brain cannot be without consequence. It is only inimical to life, there is no homeostasis, and it is always a 
burden to life’s processes. Every atom of aluminium in human brain tissue must be accommodated as aluminium 
as Al3+(aq), is highly biologically reactive. Life is robust and some aluminium in human brain tissue is tolerated 
without overt effects. We need to define such limits in the terms of both quantity and location and we need to be 
more fully aware of human exposure to aluminium. We may then live healthily in the aluminium age (https://
www.hippocraticpost.com/mens-health/the-aluminium-age/).
Methods
tissues. Brain tissues were obtained from the London Neurodegenerative Diseases Brain Bank following 
ethical approval (NRES Approval No. 08/MRE09/38+5). Donor brains were chosen on our behalf by the con-
sultant neuropathologist at the brain bank. All had a clinical diagnosis of ‘control’ while some had a pathological 
diagnosis that included age-related changes in tissue. There were five male and fifteen female donors. They were 
aged between 47 and 105 years old. Tissues were obtained from frontal, occipital, parietal and temporal lobes and 
cerebellum from all donors.
Quantitative measurements. The aluminium content of tissues was measured by an established and fully 
validated method16 that herein is described only briefly. Samples of cortex, approximately 1 g in weight, were thawed 
at room temperature and cut using a stainless steel blade into sections approximately 0.5 g in weight. Tissues were 
dried for 48 h to a constant weight in an incubator at 37 °C. Dry and thereafter weighed tissues were digested in a 
microwave (MARS Xpress CEM Microwave Technology Ltd.) in a mixture of 1 mL 15.8 M HNO3 (Fisher Analytical 
Grade) and 1 mL 30% w/v H2O2 (BDH Aristar). Resulting digests were clear with no fatty residues and, upon cooling, 
were made up to 5 mL volume using ultrapure water (cond. <0.067μS/cm). Total aluminium was measured in each 
sample by transversely heated graphite furnace atomic absorption spectrometry (TH GFAAS) using matrix-matched 
standards and an established analytical programme alongside previously validated quality assurance data. The latter 
included method blanks, detailed descriptions of which have been published recently10,16.
Figure 2. Statistical comparisons, using both mean of observations and mean of individuals, between 
aluminium content, μg/g dry wt., of brain tissue in control and disease groups. Mean and 95% confidence 
intervals are indicated. For descriptive statistics, please see Table 3.
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Statistical analyses. Comparisons between brain lobes were analysed using control group data. The control 
group dataset was well balanced with repeated measurements. Analyses were performed using the SAS general 
linear models (GLM) procedure, including gender, age and lobes as factors. Observations (OB) was the unit of 
analysis. The programme and raw data are available upon request. We considered a p-value smaller than 0.05 to 
be statistically significant using the model shown below.
= + + + +
+ +
⁎ ⁎
⁎
Model OB gender age lobe gender age gender lobe
lobe age error
:
Analysis by disease group. The distribution of aluminium content data is heavily skewed in the treatment groups. 
Data are not balanced with the number of observations and their respective lobe varying considerably between 
treatment groups. There is large variability in repeated measurements taken from the same donor. Analyses were 
performed for both the unweighted observations, and means across all lobes for each individual.
The assumption that the data across all groups are normally distributed, an assumption that underlies any 
ANOVA model, is questionable at best. A non-parametric approach was used to avoid this assumption. For the 
non-parametric tests, the SAS NPAR1WAY procedure was used, with the Dwass, Steel, Critchlow-Fligner Method 
for two-way comparisons between the different disease categories.
Null and Alternative hypothesis
H0:: µi = µj for all i≠j (No differences between means of control and disease groups)
H1: µi≠µj for some i≠j (At least one difference between means of control and disease groups)
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